US suitability petitions may be seeing renewed interest from sponsors following a surge of filings after the introduction of goal dates in October and then a drop-off of submissions after that.
Nimish Mehta, founder of the pharma-focused Indian business analytics firm Research Delta Advisors, told Generics Bulletin sister publication the Pink Sheet that the surge in suitability petitions (SPs) could be ascribed to the change in FDA guidelines as the US Food and Drug Administration works
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?